<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1646-2890</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Estomatologia, Medicina Dentária e Cirurgia Maxilofacial]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Estomatol Med Dent Cir Maxilofac]]></abbrev-journal-title>
<issn>1646-2890</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Estomatologia e Medicina Dentária]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1646-28902021000300181</article-id>
<article-id pub-id-type="doi">10.24873/j.rpemd.2021.08.843</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[A importância dos cuidados multiprofissionais no tratamento da síndrome de Stevens-Johnson associada ao uso de Dimaleato de Afatinibe: relato de caso por Equipa de Medicina Dentária Hospitalar]]></article-title>
<article-title xml:lang="en"><![CDATA[The importance of multiprofessional care in the treatment of Stevens-Johnson syndrome associated with the use of Afatinib Dimaleate: a case report by a Hospital Dentistry Team]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morais]]></surname>
<given-names><![CDATA[Jéssica Brenda Rodrigues Medeiros]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sol]]></surname>
<given-names><![CDATA[Izabella]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[Cristóvão Marcondes de Castro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Macedo]]></surname>
<given-names><![CDATA[Dhiancarlo Rocha]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade Federal de Uberlândia Hospital de Clínicas ]]></institution>
<addr-line><![CDATA[Uberlândia ]]></addr-line>
<country>Brazil</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>62</volume>
<numero>3</numero>
<fpage>181</fpage>
<lpage>185</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S1646-28902021000300181&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S1646-28902021000300181&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S1646-28902021000300181&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo A síndrome de Stevens-Johnson é relatada como uma reação incomum de hipersensibilidade tardia associada principalmente ao uso de medicamentos, e que se manifesta prioritariamente através de erupções cutâneas e ulcerações nas membranas mucosas que revestem a boca, o órgão genital e os olhos. O dimaleato de afatinibe é uma medicação inibidora da tirosina quinase que tem como alvo o recetor do fator de crescimento epidérmico, sendo indicada como monoterapia para o tratamento de carcinoma pulmonar de células não pequenas. A síndrome de Stevens-Johnson é um efeito adverso raro dessa medicação. O presente relato tem por objetivo apresentar um caso clínico de manifestação da Síndrome de Stevens-Johnson em um paciente jovem do sexo masculino após uso de dimaleato de afatinibe para tratamento de um adenocarcinoma pulmonar, com ênfase na perspetiva terapêutica odontológica em relação às manifestações orais de tal condição.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Stevens-Johnson syndrome is an uncommon delayed hypersensitivity reaction primarily associated with drug use, manifested primarily through rashes, ulcerations of the mucous membranes lining the mouth, genitals, and eyes. Afatinib dimaleate is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor and is indicated as a monotherapy for the treatment of non-small-cell lung carcinoma. The Stevens-Johnson syndrome is a rare adverse effect of that medication. The present report aims to present a unique case of Stevens-Johnson syndrome in a young male patient after afatinib dimaleate treatment for pulmonary adenocarcinoma, emphasizing the dental therapeutic perspective concerning this condition&#8217;s oral manifestations.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Afatinibe]]></kwd>
<kwd lng="pt"><![CDATA[Mucosite oral]]></kwd>
<kwd lng="pt"><![CDATA[Neoplasias pulmonares]]></kwd>
<kwd lng="pt"><![CDATA[Síndrome de Stevens-Johnson]]></kwd>
<kwd lng="en"><![CDATA[Afatinib]]></kwd>
<kwd lng="en"><![CDATA[Oral mucositis]]></kwd>
<kwd lng="en"><![CDATA[Lung neoplasms]]></kwd>
<kwd lng="en"><![CDATA[Stevens-Johnson syndrome]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emerick]]></surname>
<given-names><![CDATA[MFB]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[MMT]]></given-names>
</name>
<name>
<surname><![CDATA[Pedrosa]]></surname>
<given-names><![CDATA[DMAS]]></given-names>
</name>
<name>
<surname><![CDATA[Novaes]]></surname>
<given-names><![CDATA[MRCG]]></given-names>
</name>
<name>
<surname><![CDATA[Gottems]]></surname>
<given-names><![CDATA[LBD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de Stevens-Johnson e Necrólise Epidérmica Tóxica em um hospital do Distrito Federal]]></article-title>
<source><![CDATA[Ver Bras Enferm]]></source>
<year>2014</year>
<volume>67</volume>
<page-range>898-904</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fakoya]]></surname>
<given-names><![CDATA[AOJ]]></given-names>
</name>
<name>
<surname><![CDATA[Omenyi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Anthony]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Anthony]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Etti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Otohinoyi]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities]]></article-title>
<source><![CDATA[Open Access Maced J Med Sci]]></source>
<year>2018</year>
<volume>6</volume>
<page-range>730-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrasquillo]]></surname>
<given-names><![CDATA[OY]]></given-names>
</name>
<name>
<surname><![CDATA[Santiago-Vazquez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cardona]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz-Manzano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study]]></article-title>
<source><![CDATA[Int J Dermatol]]></source>
<year>2019</year>
<volume>58</volume>
<page-range>1293-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nühnen]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Schön]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Mössner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib]]></article-title>
<source><![CDATA[J Dtsch Dermatol Ges]]></source>
<year>2018</year>
<volume>16</volume>
<page-range>199-201</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doesch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Debus]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Papadopoulos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schultz]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Ficker]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient]]></article-title>
<source><![CDATA[Lung Cancer]]></source>
<year>2016</year>
<volume>95</volume>
<page-range>35-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sawada]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ohmori]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Omoto]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Haruyama]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshioka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fixed drug eruption-like macules caused by febuxostat]]></article-title>
<source><![CDATA[Eur J Dermatol]]></source>
<year>2016</year>
<volume>26</volume>
<page-range>412-3</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marinis]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Catania]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Passaro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Afatinib in NSCLC harbouring EGFR mutations]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>e148-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pei]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Schuler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical perspective of afatinib in non-small cell lung cancer]]></article-title>
<source><![CDATA[Lung Cancer]]></source>
<year>2013</year>
<volume>81</volume>
<page-range>155-61</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bulisani]]></surname>
<given-names><![CDATA[ACP]]></given-names>
</name>
<name>
<surname><![CDATA[Sanches]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Vendrame]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de Stevens-Johnson e necrólise epidérmica tóxica em medicina intensiva]]></article-title>
<source><![CDATA[Rev Bras Ter Intensiva]]></source>
<year>2006</year>
<volume>18</volume>
<page-range>292-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Köstler]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hejna]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zielinski]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2001</year>
<volume>51</volume>
<page-range>290-315</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez-Moles]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Archilla]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Isabel]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Moles]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution]]></article-title>
<source><![CDATA[Oral Surg Oral Med Oral Pathol Oral Radiol Endod]]></source>
<year>2002</year>
<volume>93</volume>
<page-range>264-70</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cronshaw]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Anagnostaki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mylona]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Grootveld]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Photobiomodulation and Oral Mucositis: A Systematic Review]]></article-title>
<source><![CDATA[Dent J]]></source>
<year>2020</year>
<volume>8</volume>
<page-range>87</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simões]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Freitas]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Bello-Silva]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Tunér]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Eduardo]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Laser phototherapy for Stevens-Johnson syndrome: a case report]]></article-title>
<source><![CDATA[Photomed Laser Surg]]></source>
<year>2011</year>
<volume>29</volume>
<page-range>67-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[LFM]]></given-names>
</name>
<name>
<surname><![CDATA[Cunha]]></surname>
<given-names><![CDATA[NDS]]></given-names>
</name>
<name>
<surname><![CDATA[Lanza]]></surname>
<given-names><![CDATA[CRM]]></given-names>
</name>
<name>
<surname><![CDATA[Travassos]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of oral manifestations of toxic epidermal necrolysis with low-level laser therapy in a pediatric patient]]></article-title>
<source><![CDATA[Pediatr Dermatol]]></source>
<year>2019</year>
<volume>36</volume>
<page-range>e27-30</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
